Skip to content

July News Round Up

๐‰๐ฎ๐ฅ๐ฒ ๐๐ž๐ฐ๐ฌ ๐‘๐จ๐ฎ๐ง๐ ๐”๐ฉ

๐Ÿ‘€ ๐๐š๐ฎ๐ฌ๐œ๐ก & ๐‹๐จ๐ฆ๐› ๐€๐œ๐ช๐ฎ๐ข๐ซ๐ž๐ฌ ๐“๐ซ๐ฎ๐ค๐ž๐ซ๐š ๐Œ๐ž๐๐ข๐œ๐š๐ฅ: ๐„๐ฑ๐ฉ๐š๐ง๐๐ข๐ง๐  ๐ˆ๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐จ๐ง๐ฌ ๐ข๐ง ๐ƒ๐ซ๐ฒ ๐„๐ฒ๐ž ๐ƒ๐ข๐š๐ ๐ง๐จ๐ฌ๐ข๐ฌ
Bausch + Lomb has acquired Trukera Medical, an ophthalmic diagnostics leader, through an affiliate. This acquisition introduces the innovative ScoutPro, a portable osmolarity system launched in October 2022. The ScoutPro, Trukeraโ€™s first product since rebranding, provides an all-in-one solution for measuring tear osmolarity to diagnose dry eye disease (DED).

As the only portable osmometer in the U.S., ScoutPro enhances diagnostics with its automated capabilities. Bausch & Lomb expects this "tuck-in" acquisition to strengthen their surgical offerings and solidify their leading position in the dry eye treatment market. Integrating ScoutProโ€™s technology marks a significant step in advancing eye care.

๐Ÿ‘€ ๐„๐ฌ๐ฌ๐ข๐ฅ๐จ๐ซ๐‹๐ฎ๐ฑ๐จ๐ญ๐ญ๐ข๐œ๐š ๐€๐œ๐ช๐ฎ๐ข๐ซ๐ž๐ฌ ๐Œ๐š๐ฃ๐จ๐ซ๐ข๐ญ๐ฒ ๐’๐ญ๐š๐ค๐ž ๐ข๐ง ๐‡๐ž๐ข๐๐ž๐ฅ๐›๐ž๐ซ๐  ๐„๐ง๐ ๐ข๐ง๐ž๐ž๐ซ๐ข๐ง๐ 
EssilorLuxottica has acquired an 80% stake in Heidelberg Engineering, a leader in optical coherence tomography (OCT) and digital surgical navigation technologies. Heidelberg Engineering will continue operating independently under its brand, enhancing EssilorLuxottica's capabilities in early detection and diagnosis.

๐Ÿ‘€ ๐€๐๐ˆ ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐š๐ฅ๐ฌ ๐ญ๐จ ๐€๐œ๐ช๐ฎ๐ข๐ซ๐ž ๐€๐ฅ๐ข๐ฆ๐ž๐ซ๐š ๐’๐œ๐ข๐ž๐ง๐œ๐ž๐ฌ ๐Ÿ๐จ๐ซ $381 ๐Œ๐ข๐ฅ๐ฅ๐ข๐จ๐ง
ANI Pharmaceuticals, Inc. will acquire Alimera Sciences Ophthalmologie GmbH for $381 million, aiming to enhance its Rare Disease business and strengthen its presence in ophthalmology, specifically in DME and Uveitis. The deal is expected to finalise by late Q3 2024, pending regulatory approvals, with projected revenues of $105 million in 2024.

๐Ÿ‘€ ๐“๐ก๐ž ๐„๐ฏ๐จ๐ฅ๐ฏ๐ข๐ง๐  ๐‹๐š๐ง๐๐ฌ๐œ๐š๐ฉ๐ž ๐จ๐Ÿ ๐”๐Š ๐„๐ฒ๐ž ๐‚๐š๐ซ๐ž: ๐๐š๐ฅ๐š๐ง๐œ๐ข๐ง๐  ๐๐ซ๐ข๐ฏ๐š๐ญ๐ž ๐š๐ง๐ ๐๐‡๐’ ๐’๐ž๐ซ๐ฏ๐ข๐œ๐ž๐ฌ
Nearly 60% of NHS cataract surgeries are now performed by private providers to address the COVID-19 backlog, reducing waiting times but causing controversy. A survey revealed 58% of hospital eye units believe this shift negatively impacts patient care. The role of High Street optometrists in providing primary eye care has been emphasized, suggesting they could support community and tertiary care.

๐Ÿ‘€ ๐€๐Ž๐ ๐Ž๐ฎ๐ญ๐ฅ๐ข๐ง๐ž๐ฌ ๐Š๐ž๐ฒ ๐๐ซ๐ข๐จ๐ซ๐ข๐ญ๐ข๐ž๐ฌ ๐Ÿ๐จ๐ซ ๐ญ๐ก๐ž ๐๐ž๐ฑ๐ญ ๐†๐จ๐ฏ๐ž๐ซ๐ง๐ฆ๐ž๐ง๐ญ
Ahead of the UK general election, the Association of Optometrists (AOP) has highlighted three priorities:
๐Ÿ‘ Expanding community eye care services.
๐Ÿ‘ Updating the medication prescribing powers of optometrists.
๐Ÿ‘ Investing in IT infrastructure to improve image sharing and communication between clinicians